1. Introduction {#sec0005}
===============

The dramatic change of events with the recent unprecedented coronavirus pandemic declared by the World Health Organisation (WHO) has prompted an exponential increase of scientific interest in coronaviruses globally. As of April 22nd 2020, the pandemic has resulted in 2,553,112infections, with 177,286 deaths worldwide, which continues to drastically increase as we write (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>).

Coronaviruses (CoVs) belong to the family Coronaviridae, subfamily *Coronavirinae* and are large (genome size 26−32 kb; [@bib0520]), enveloped, positive-sense single-stranded ribonucleic acid (RNA) viruses that can infect both animals and humans ([Fig. 1](#fig0005){ref-type="fig"} ). Based on their genotypic and serological characteristics, the viruses are subdivided into four genera: *Alpha*-, *Beta*-, *Gamma*-, and *Deltacoronavirus* ([@bib0050]; [@bib0275]). At present, all identified CoVs that are capable of infecting humans belong to the first two genera. These include the alphacoronaviruses (αCoVs) HCoV-NL63 (Human CoV-NL63) and HCoV-229E and the betacoronaviruses (βCoVs) HCoV-OC43 (Human CoV-OC43), HKU1 (Human CoV), SARS-CoV (Severe Acute Respiratory Syndrome CoV), and MERS-CoV (Middle Eastern Respiratory Syndrome CoV) ([@bib0275]). In the past two decades there have been three epidemics caused by the betaCoVs, namely SARS in 2002−03, MERS in 2012 and COVID-19, first identified in 2019 ([@bib0550]).Fig. 1The general structure of a coronavirus (reproduced from Wikipedia under CC licence 4.0). E protein = envelope protein.Fig. 1

SARS-CoV emerged in 2002−03 in Southern China, causing a global threat and infecting more than 8000 people, with approximately 800 fatalities recorded, largely in China and the surrounding regions ([@bib0275]; [@bib0360]). MERS-CoV emerged in the Middle East, spreading to several countries to infect close to 2300 individuals, resulting in 845 deaths as of July 2019 ([@bib0515]). The present CoV pandemic resulting from SARS-CoV-2, which causes COVID-19 (coronavirus disease), was identified in Wuhan City, in the Hubei province of southern mainland China on the 31st December 2019 ([@bib0415]). The genome of SARS-CoV-2 is approximately 70 % identical to that of SARS-CoV ([@bib0125]), hence leading to its current name.

The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) proteins ([@bib0525]). The S proteins interact directly with human angiotensin-converting enzyme (ACE) 2, allowing the virus to enter the cells. At present, no preventive vaccines or established antiviral therapies are available for coronaviruses ([@bib0415]). However, several synthetic compounds have shown promise, including hydroxychloroquine and choloroquine phosphate ([@bib0060]; [@bib0080]), which act through several mechanisms, including alkalisation of the host cell phagolysosomes. Newer antiviral medications such as lopinavir ([@bib0555]), remdesivir ([@bib0110]; [@bib0490]), and arbidol ([@bib0165]) also show promise. Other suggested treatment options include lopinavir/ritonavir, nucleoside analogues, neuraminidase inhibitors, and peptide EK1 ([@bib0270]). A detailed list of current and planned clinical trials investigating various drugs for the treatment of SARS-CoV-2 was provided by [@bib0355], with updated results available from [@bib0055].

In addition, traditional herbal medicines and purified natural products may guide the development of novel antiviral drugs. In other words, more efficient drugs can often be designed based on the structure of natural compounds that exhibit the desired activity. Classic examples of this drug discovery pathway include emetine, an isoquinoline alkaloid isolated from *Cephaelis ipecacuanha* and used as an amoebicidal drug; quinine, derived from the bark of *Cinchona* trees; and numerous other drugs modified from natural compounds, such aspirin, morphine and paclitaxel, an antineoplastic drug used for the treatment of cancer ([@bib0075]). Indeed, half of all drugs approved between 1981 and 2014 were derived from or mimicked a natural compound ([@bib0340]). Furthermore, in the current outbreak of COVID-19, many patients appear to be turning to complementary or traditional medicinal therapies, albeit using them almost exclusively in conjunction with western medicine. For example, one study suggested that almost 92 % of 135 hospitalised patients in northeast Chonqing (China) received traditional Chinese medicine in addition to western medicine ([@bib0470]). However, based on the many studies conducted on this topic, it is hard to separate the potential effects of, and interaction between, traditional Chinese herbal medicine and western medicine. Recent reviews have suggested that traditional Chinese medicine could be used for the prevention ([@bib0290]) or treatment ([@bib0545]) of COVID-19; while still acknowledging that many studies involving clinical trials are poorly designed or controlled, and the choice of treatments is largely empirically based. As previous work has highlighted the potential of traditional Chinese medicines as a source of potential novel drugs ([@bib0255]), we have not included details on such studies investigating the antiviral activity of remedies comprising portions of numerous plant species in this review. Rather, our aim is to collate data on the broad spectrum of natural phytochemicals from individual plant species that may have therapeutic potential.

Naturally occurring antiviral agents acting against general coronaviruses were briefly reviewed by [@bib0245] six years ago, while more recent reviews by [@bib0355] and [@bib0270] on therapies for COVID-19 made only brief mention of natural therapeutics and did not explore the active compounds or their mechanism of action. In light of the current COVID-19 pandemic, this review aims to gather and consolidate information on extracts and compound(s) derived from natural products which show potential antiviral bioactivity for the inhibition of coronaviruses. It is hoped that the information presented may guide the naturally-derived drug discovery process in finding a treatment for SARS-CoV-2.

2. Methods {#sec0010}
==========

The PubMed database ([www.ncbi.nlm.nih.gov/pubmed/](http://www.ncbi.nlm.nih.gov/pubmed/){#intr0015}) was used to locate articles including the following combination of terms: (coronavirus, SARS OR MERS) AND (traditional medicine, herbal, remedy OR plants). Papers primarily focussed on the antiviral activity of prepared Chinese traditional medicines, which typically comprise multiple plant species, were considered out of scope of this review. All articles up to and including 25 March 2020 were considered, yielding a total of 659 results. Two of the authors independently screened the results and identified relevant articles, yielding a total of 35 primary articles on human coronaviruses and 22 on animal coronaviruses were found to be pertinent and thus included in this review (total = 58 papers). Of these, two papers (6 %) were on SARS-CoV-2 (COVID-19). The majority of studies on human coronaviruses (69 %; n = 24) included SARS-CoV, with only 3 (9 %) including MERS-CoV and 8 (23 %) other human coronaviruses. It should be noted that one study included both SARS-CoV and MERS-CoV ([@bib0350]) while another included both MERS-CoV and HCoV-229E ([@bib0330]), hence these percentages do not add to 100 %.

 {#sec0015}

[Table 1](#tbl0005){ref-type="table"} summarises the studies reporting the inhibition of various human coronavirus strains using compounds derived from plant sources. The table is arranged by viral strain in order to better compare the bioactivity of compounds from different studies upon the same viral genotypes. Where identified, the key compounds responsible for the antiviral activity and their identified mechanisms of action are presented. It should be noted the term EC~50~ (effective concentration) applies to cell-based assays, while IC~50~ (inhibitory concentration) applies to enzyme- or biochemical-based assays.Table 1Studies reporting antiviral activity of natural products or isolates against human coronavirus strains.Table 1Viral strainAssay methodPlant speciesPlant part/ isolateEC~50~ or IC~50~ (μM unless otherwise stated)SIKey compounds present (if identified)Biological actionReferenceSARS-CoV-2Computer modellingPresent in: *Camellia sinensis*--NDNDTheaflavinBinding to RNA-dependent RNA polymerase([@bib0280])SARS-CoV-2Computer modellingCompounds previously identified in a range of Chinese traditional medicinesn/aNDNDBetulinic acidReplication & 3CLpro([@bib0580])CoumaroyltyraminePLpro & 3CLproCryptotanshinonePLpro & 3CLproDesmethoxyreserpineReplication, 3CLpro & entryDihomo-c-linolenic3CLproDihydrotanshinoneEntry & spike proteinKaempferolPLpro & 3CLproLignanReplication & 3CLproMoupinamidePLproN-cis-feruloyltyraminePLpro & 3CLproQuercetinPLpro & 3CLproSugiolReplication & 3CLproTanshinone IIaPLpro & 3CLproSARS-CoVCPE assay*Boenninghausenia sessilicarpa*Isolated compound from ethanol extract∼450NDLeptodactyloneNot determined([@bib0530])SARS-CoVCPE assay*Hippeastrum* hybridLectins isolated from diaminopropane extracts3.2 ± 2.8\>31.3Agglutinins: mannose-specificInhibit viral attachment and another target at end of replication cycle([@bib0160])*Galanthus nivalis*6.2 ± 0.6\>16.1*Narcissus pseudonarcissus*5.7 ± 4.4\>17.5*Lycoris radiata*48\>2.1*Allium porrum*0.45 ± 0.0\>222.2*Allium ursinum*8\>5.5*Cymbidium* hybrid18 ± 4\>20*Listera ovata*4.9 ± 0.8\>45.5*Epipactis helleborine*2.2 ± 1.3\>55.5*Tulipa* hybrid1.8 ± 0.3\>2.3*Morus nigra*22 ± 6\>62.5*Nicotiana tabacum*1.6 ± 0.5\>58.8GlcNAc-specific*Urtica dioica*1.7 ± 0.3\>76.9(GlcNAc)*~n~*-specific*Morus nigra*1.3 ± 0.1\>2Gal-specific*Cladastris lutea*50 ± 13\>13.5Man/Glc-specific*Polygonatum*7.4 ± 0.2\>5.5Gal/GalNAc-specific*multiflorum*18 ± 13\>12.6GalNAc(\>Gal) specific*Iris* hybrid28 ± 1122.7GalNAcα(1.3)Gal \> Gal NAc \> Gal-specific2.2 ± 0.98.24.4 ± 3.116.2*Tulipa* hybrid3.4 ± 2.0\>1.3Man/GalNAc-specific38 ± 0 (all μg/mL)SARS-CoV (BJ001 and BJ006)CPE/MTS assay*Artemisia annua*95 % EtOH extract34.5−39.227−31In *L. radiata*: lycorineNot determined([@bib0225])*Pyrrosia lingua*Chloroform40.5−43.255−59*Lindera aggregate*95 % EtOH80.6−88.216−17*Lycoris radiata*95 % EtOH2.1−2.4 (all μg/mL)370−422Isolated lycorine48.8 ± 3.6 nM954Commercial lycorine15.7 ± 1.2  nM885SARS-CoV BJ01MTT cytotoxicity assay*Galla chinensis*Isolated compounds from 85 % ethanol extract10.614.622LuteolinBinds with S2 subunit and preventing entry([@bib0560])4.540.0Tetra-*O*-galloyl-β-D-glucoseSARS-CoV FFM1CPE assay*Toona sinensis*Boiled water extract of leaves30−43 μg/mL12−17Not determinedNot determined([@bib0015])SARS-CoV FFM1CPE assayGlycyrrhizin and glycyrrhetinic acid found in: *Glycyrrhiza radix*Chemical standards365 ± 12\>65GlycyrrhizinNot determined([@bib0105])\>20--18β-glycyrrhetinic acid40 ± 13\>75Selected synthetic derivatives35 ± 741139 ± 2028 ± 2650 ± 1055 ± 3316 ± 14SARS-CoV FFM1CPE assay*Laurus nobilis*Essential oil120 ± 1.2 μg/mL4.2*L. nobilis*: β-ocimene, 1,8-cineole, α-pinene, β-pineneInhibition of viral replication([@bib0265])*Thuja orientalis*130 ± 0.4 μg/mL3.8*T. orientalis*: α-pinene, δ-3-carene, α-cedrolSARS-CoV (Hong Kong strain)CPE assay*Cibotium barometz*75 % ethanol8.42-\>10\>59.4Not determinedNot determined([@bib0495])*Gentiana scabra*extract8.70\>57.5Secoiridoid & glycosides?*Dioscorea batatas*8.06\>62.0Polysaccharides?*Cassia tora*8.43\>59.3Emodin?*Taxillus chinensis*5.39 (all μg/mL)\>92.8Quercetin?SARS-CoV PUMC01 F5Plaque reduction assay*Cinnamomi* sp.Water extraction followed by phase extraction10.7 ± 0.4 μg/mL (EtOH fraction)16.9Procyanidin A2Early stage inhibition of viral entry (clathrin-dependent endocytosis pathway)([@bib0595])7.8 ± 0.3 μg/mL23.1(butanol fraction)Isolated compound29.9 ± 3.3 μM37.35SARS-CoV *urbani* strain (200,300,592)Neutral red uptake assay SARS-CoV-infected BALB/c mouse modelFound in: *Urtica dioica*Chemical standard used2.6 ± 3.7 μg/mL10.2 ± 5.6*Urtica dioica* agglutininDose-dependent inhibition of viral replication, likely in adsorption or penetration stages. Binds to SARS-CoV spike glycoprotein and N-acetylglucosamine-like residues on the glycosylated envelope([@bib0200])SARS-CoVCPE assayFound in *Griffithsia* sp.Chemical standard used(μg/mL)GriffithsinDirect binding to surface envelope glycoprotein spike([@bib0350])*Urbani* strain0.61\>164*Tor-II* strain0.61\>164*CuHK* strain0.78\>128*Frank* strain1.19\>83SARS-CoV helicase nsP13Fluorometric helicase activity assayn/aChemical standard2.71 ± 0.19NDMyricetinInhibit ATPase activity of SARS-CoV helicase nsP13([@bib0575])*Scutettaria baicalensis*Isolated compounds0.86 ± 0.48ScutellareinSARS-CoV S proteinImmunofluorescence assay (IFA)*Rheum officinale*Water extracts (at 40 °C) of roots∼5 μg/mLNDEmodinInhibited binding of S protein to ACE2([@bib0100])*Polygonum multiflorum*Synthetic emodin standard1−5 μg/mL200 μMSARS-CoV 3CLproComputer modellingCompounds from marine natural products database and traditional Chense medicines databasen/an/an/a18 compounds identified: M3927, M4367, M4890, M5410, M5789, M6601, M6602, T1434, T1441, T2826, T2831, T4744, T537, T5656, T6791, T8593, T3091, T5242Inhibition of 3CLpro([@bib0260])SARS-CoV CLproComputer modellingIdentified via computer modelling. Found in: *Veratrum sabadilla*n/aNDNDSabadinineInhibition of CoV protease([@bib0450])SARS-CoV CLproComputer modelling for compounds docking in cathepsin-L proteaseFound in: *Artemisia annua*n/aNDNDAurantiamide acetateInhibition of active pocket of CoV protease([@bib0480])SARS-CoV 3CLpro3CLpro cleavage assay*Isatis indigotica*Water extract of roots53.8 ± 4.2 μg/mL\>92.9Inhibition of 3CLpro([@bib0240])Isolated compounds121 μM\>99.4Sinigrin300 μM24.6Indigo115 μM12.8β-sitosterol132 μM87.8Aloe-emodin60 μM45.3HesperetinSARS-CoV 3CLpro3CLpro inhibition test*Rheum palmatum*75 % ethanol13.76 ± 0.03 μg/mLNDPossibly anthraquinonesInhibition of 3CLpro([@bib0285])SARS-CoV CLproCLpro inhibition assay*Salvia miltiorrhiza*Isolated compounds from ethanol extract89.1 ± 5.2NDTanshinone IIANon-competitive enzyme isomerization inhibitor of protease (except for rosmariquinone which exhibits simple reversible slow-binding inhibition)([@bib0365])24.8 ± 0.8Tanshinone IIB21.1 ± 0.8Methyl tanshinonate226.7 ± 6.2Cryptotanshinone38.7 ± 8.2Tanshinone I14.4 ± 0.7Dihydrotanshinone I21.1 ± 0.8RosmariquinoneSARS-CoV CLproCLpro inhibition assay*Torreya nucifera*Isolated compounds from ethanol extract8.3 ± 1.2NDAmentoflavoneNon-competitive inhibition of CoV CLpro([@bib0390])72.3 ± 4.5Bilobetin32.0 ± 1.7Ginkgetin38.4 ± 0.2SciadopitysinSARS-CoV CLproCLpro inhibition assay*Tripterygium regelii*Isolated compounds from 95 % methanol extract of bark10.3 ± 0.2NDCelastrolCompetitive inhibition of CoV protease([@bib0395])5.5 ± 0.7Pristimererin9.9 ± 0.1Tingenone2.6 ± 0.3IguesterinSARS-CoV 3CLproFluorogenic 3CLpro inhibition assay*Houttuynia cordata*Boiled water extract∼1000 μg/mLNDNot determinedMinor 3CLpro inhibition. May inhibit pivotal enzymes and trigger negative feedback control in immune systems([@bib0205])SARS-CoV PLproPLpro inhibition assay*Salvia miltiorrhiza*Isolated compounds from ethanol extract1.6 ± 0.5NDTanshinone IIANon-competitive enzyme isomerization inhibitor of protease (except for rosmariquinone which exhibits simple reversible slow-binding inhibition)([@bib0365])10.7 ± 1.7Tanshinone IIB9.2 ± 2.8Methyl tanshinonate0.8 ± 0.2Cryptotanshinone8.8 ± 0.4Tanshinone I4.9 ± 1.2Dihydrotanshinone I30.0 ± 5.5RosmariquinoneSARS-CoV PLproPLpro inhibition assay*Broussonetia*\
*papyrifera*Isolated compounds from ethanol extract3.7 ± 1.6ND3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavaneNon-competitive inhibition of CoV PLpro([@bib0370])SARS-CoV PLproFluorogenic PLpro inhibition assay*Psoralea corylifolia*Ethanol extract of seeds15 μg/mLMixed inhibitor of SARS-CoV PLpro (isobavachalcone and psoralidin also reversible)([@bib0185])38.4 ± 2.4Bavachinin18.3 ± 1.1Neobavaisoflavone7.3 ± 0.8Isobavachalcone10.1 ± 1.24′-O-methylbavachalcone4.2 ± 1.0Psoralidin32.3 ± 3.2 (rest in μM)Corylifol ASARS-CoV *urbani* strain PLproFluorogenic protease activity assay*Paulownia tomentosa*Methanol extracts of fruit6.2 ± 0.04NDTomentin AReversible, mixed-type (allosteric) inhibitors of PLpro([@bib0040])6.1 ± 0.02Tomentin B11.6 ± 0.13Tomentin C12.5 ± 0.22Tomentin D5.0 ± 0.06Tomentin EMERS-CoV EMC/2012Luciferase assayFound in *Griffithsia* sp.Chemical standard/pure isolate used∼0.125 μg/mLNDGriffithsinDirect inhibition of protein spikes preventing viral binding([@bib0320])MERS-CoV EMC/2012Cellular dual luciferase reporter assayFound in *Aglaia* sp.Chemical standard used1.3\>7690SilvestrolSpecific inhibitor of RNA helicase eIF4A([@bib0330])MERS-COV PLproPLpro inhibition assay*Broussonetia papyrifera*Isolated compounds from ethanol extract39.5 ± 5.1NDKazinol FNon-competitive inhibition of CoV PLpro([@bib0370])42.1 ± 5.0Broussochalcone AHCoV-229EXTT assay*Calophyllum blancoi*Isolated compounds from acetone extract of roots3NDBlancoxanthoneNot determined([@bib0405])15PyranojacareubinHCoV-229EXTT assayFound in: *Bupleurum* spp., *Heteromorpha* spp. and *Scrophularia scorodonia*Chemical standards used8.6 ± 0.326.6Saikosaponin APossible interference in early stage of viral replication, e.g. absorption and penetration([@bib0030])1.7 ± 0.1221.9Saikosaponin B~2~19.9 ± 0.119.2Saikosaponin C13.2 ± 0.313.3Saikosaponin DHCov-229ECPE assay*Pelargonium sidoides*EPs® 7630 (proprietary extract using 11 % ethanol)44.50 ± 15.84 μg/mL\>2.3Not determinedPossibly interference of virus surface resulting in viral inactivation([@bib0305])HCoV-229ECellular dual luciferase reporter assayFound in *Aglaia* sp.Chemical standard used3\>3330SilvestrolSpecific inhibitor of RNA helicase eIF4A([@bib0330])HCoV-NL63Plaque viricidal assay*Strobilanthes cusia* leafMethanol extract0.64 μg/mL\>156Blocking viral RNA genome synthesis and papain-like protease 2 activity([@bib0455])Isolated compounds0.06\>6600Tryptanthrin2.09\>191Indigodole BHCoV-NL63Virus yield reduction assay*Sambucus formosana*Ethanol extract of stem1.17 ± 0.75 (μg/mL)∼154([@bib0500])Isolated compounds3.54 ± 0.77\>141Caffeic acidInhibits cell docking43.5 ± 6.0\>11Chlorogenic acidNot determined71.5 ± 18.4\>7Gallic acidNot determinedHCoV-OC43CPE assay and neutral red assayFound in *Griffithsia* sp.Chemical standard used0.048−0.16320-\>2100GriffithsinDirect binding to surface envelope glycoprotein spike([@bib0350])HCoV-299E0.18−0.33\>30−56HCoV-NL63\<0.0032 (all μg/mL)\>3100HCoV-OC43MTS assay and *q*RT-PCRFound in: *Stephania tetrandra* and related speciesChemical standards used0.33 ± 0.03\>40.2TetrandrineInhibit viral replication and expression of viral S and N protein([@bib0190])1.01 ± 0.0711.5Fangchinoline0.83 ± 0.0713.6Cepharanthine[^2]

3.1. Inhibitors of SARS-CoV-2 (COVID-19) {#sec0020}
----------------------------------------

Few studies report on SARS-CoV-2, as expected given the short time since its emergence. However, a number of studies report on use of computer modelling for screening purposes ([@bib0260]; [@bib0280]; [@bib0450]; [@bib0480]; [@bib0580]). Typically, these models determine the free binding of energy between a ligand and a receptor ([@bib0070]), with a lower free binding energy indicating a stronger bond between the ligand and receptor. Although obtaining consistent results via different modelling approaches can be challenging ([@bib0005]), computer modelling nevertheless allows for comparison of the relative binding affinity of bank of molecules toward the receptor in question.

In addition to reducing the high costs and length of time associated with physically screening large banks of compounds or plant extracts for bioactivity ([@bib0025]), the speed and versatility of this method may be particularly valuable for rapidly finding a potent inhibitor of SARS-CoV-2. Compounds that are highlighted through this method can then be forwarded on cell-based assays to assess their *in vitro* effectiveness and toxicity, before continuing to animal and clinical trials.

[@bib0280] virtually screened 83 compounds found in Chinese traditional medicines for activity against the RNA-dependent RNA polymerase of SARS-CoV-2, identifying theaflavin, an antioxidant polyphenol, as a potential inhibitor. Similarly, [@bib0580] virtually screened 115 compounds found in Chinese traditional medicines, highlighting 13 for further studies. Several of these were naturally occurring polyphenolic compounds such as quercetin and kaempferol, which have already received considerable interest for the treatment of other disease types ([@bib0010]; [@bib0170]; [@bib0445]).

3.2. Inhibitors of SARS-CoV {#sec0025}
---------------------------

Given the relatively large amount of research that has been performed searching for inhibitors of SARS-CoV, antiviral agents that successfully inhibit this viral strain may provide a good starting point for identifying compounds that are active against SARS-CoV-2.

### 3.2.1. Virtual screening {#sec0030}

Several authors have utilised virtual computer docking models to screen for potential compounds that could bind to and inhibit key proteins present in SARS-CoV ([@bib0260]; [@bib0450]; [@bib0480]), highlighting the potential antiviral activity of compounds such as sabadinine and aurantiamide acetate. Compounds may be screened against a number of binding sites in order to test for potential inhibition of coronaviruses; the main sites that are typically used are the chymotrypsin-like protease (3CLpro), papain like protease (PLpro), spike proteins and RNA-dependent RNA polymerase.

### 3.2.2. Compound library screening {#sec0035}

Several large *in vitro* screening studies searching for inhibitory activity of naturally occurring compounds against SARS-CoV have been performed, mainly on Chinese medicinal herbs ([@bib0225]; [@bib0475]). While the results highlight the potential of selected plant extracts against SARS-CoV, they also demonstrate that such work can be akin to searching for a 'needle in a haystack'. For example, [@bib0225] screened over 200 ethanol/chloroform extracts of Chinese medicinal herbs and found only four (*Lycoris radiata, Artemisia annua, Pyrrosia lingua* and *Lindera aggregata*) with moderate to high antiviral activity using a CPE assay (EC~50~ values ranging from 2.4 ± 0.2--88.2 ± 7.7 μg/mL). Of these, a single compound (lycorine) from one plant species (L. *radiata*) was earmarked as a potential drug candidate against SARS-CoV. The antiviral efficacy of lycorine was quite high (EC~50~ of 15.7 ± 1.2 nM), with a selectivity index greater than 900. Although the authors did not make mention of this fact, lycorine can cause toxic effects at low dosage levels (around 1 mg/kg in dogs) ([@bib0195]), hence great caution would be required for further development of this compound as a drug candidate.

[@bib0575] screened the activity of a library of 64 naturally occurring compounds against SARS-CoV helicase, which plays a key role in the viral genome replication, transcription, and translation. The polyphenolics myricetin and scutellarein ([Fig. 2](#fig0010){ref-type="fig"} ) were identified as the most promising candidates (IC~50~ values of 2.71 ± 0.19 and 0.86 ± 0.48 μM, respectively). Although the antiviral activity of the compounds was not assessed in cell-based assays, the authors did report that neither compound was toxic to normal (non-tumorigenic) breast epithelial cells. Myricetin is found in reasonably high concentrations in fruits such as cranberry ([@bib0090]) as well as in several vegetables such as *Calamus scipionum* and garlic ([@bib0315]). Scutellarein was isolated from *Scutellaria baicalensis* (Chinese Skullcap), which has been traditionally used in the treatment of inflammation and respiratory infections, amongst other uses ([@bib0585]). Both compounds were found to inhibit SARS-CoV helicase (nsP13) through the inhibition of ATPase activity, but did not directly inhibit helicase activity. This appeared to be the only publication identifying naturally occurring compounds as inhibitors of SARS-CoV helicase.Fig. 2The structure of selected naturally occurring compounds that demonstrate promising anti-coronavirus activity. **(1)** Quercetin **(2)** Quercetin 7-rhamnoside **(3)** Myricetin **(4)** Psoralidin **(5)** Caffeic acid **(6)** Tryptanthrin **(7)** Lycorine **(8)** Scutellarein **(9)** Silvestrol **(10)** Saikosaponin B2 **(11)** Isobavachalcone **(12)** Griffithsin. As annotated on **(4)**, note the aromatic rings and substituted fused rings present in most compounds.Fig. 2

The need to isolate and synthesise more active agents as part of the development pipeline was highlighted in a study by [@bib0385]. The authors reported that the Chinese herbal medicine Lianhuaqingwen (comprised of a mixture of plant species) showed antiviral activity against SARS-CoV-2; however, the EC~50~ was quite high (∼411 μg/mL). For comparison, the commercial drug remdesivir showed an EC~50~ of 0.651 μM (approx. 0.39 μg/mL) using the same assay ([@bib0385]). This also underscores the potential lack of potency in some traditional medicines promoted for the treatment of coronavirus symptoms.

### 3.2.3. Polyphenols {#sec0040}

One family of compounds that demonstrate antiviral activity across a number of studies is the polyphenols. For example, quercetin ([Fig. 3](#fig0015){ref-type="fig"} ) showed an IC~50~ of 8.6 ± 3.2 μM against SARS-CoV PLpro ([@bib0370]). No cell-based assay of antiviral activity was performed. Quercetin ([Fig. 2](#fig0010){ref-type="fig"}) is a flavonoid found in many foods, but in particularly high levels in certain berries and herbs ([@bib0140]; [@bib0145]). As previously mentioned (section [3.2.2](#sec0035){ref-type="sec"}), the structurally similar polyphenolics myricetin and scutellarein ([Fig. 2](#fig0010){ref-type="fig"}) display reasonable levels of inhibitory activity against SARS-CoV helicase ([@bib0575]).Fig. 3Possible binding sites of quercetin in SARS-CoV-2 3CLpro and tryptanthrin in PLpro. Docking was performed in AutoDock Vina 1.1.2 (Trott and Olson, 2010) against target proteins generated by SWISS-MODEL (<https://swissmodel.expasy.org/repository/species/2697049>).Fig. 3

Bioassay-guided fractionation of the ethanolic extract obtained from *Psoralea corylifolia* seeds has also identified polyphenolics as the bioactive compounds responsible for the activity of this plant species against SARS-CoV PLpro ([@bib0185]). Furthermore, six phenolic phytochemicals were isolated from the ethanolic extracts - identified as bavachinin, neobavaisoflavone, isobavachalcone, 4′-O-methylbavachalcone, psoralidin and corylifol A - with their antiviral activity varying widely (IC~50~ values between 4.2--38.4 μM). Again, no cell-based antiviral assays were performed. Isobavachalcone and psoralidin ([Fig. 2](#fig0010){ref-type="fig"}) showed the greatest antiviral activity, with both found to be mixed, reversible inhibitors of PLpro through a type I mechanism (i.e. preferentially bind to the free enzyme, rather than the enzyme substrate complex) ([@bib0185]).

### 3.2.4. Lectins {#sec0045}

Plant lectins, which are proteins that can bind specifically and reversibly to carbohydrate groups ([@bib0325]), are another group of naturally occurring compounds that may inhibit SARS-CoV. Lectins have shown promise as antiviral agents against viruses such as influenza and herpes simplex virus ([@bib0130]), as well as Ebola ([@bib0065]; [@bib0310]). Remarkably, elevating the plasma levels of recombinant human mannose-binding lectin in mice allowed them to survive otherwise fatal Ebola infections ([@bib0310]). [@bib0160] screened the activity of a broad range of plant lectins (33 in total) against SARS-CoV using a cytopathicity effect (CPE) assay, finding EC~50~ values as low as 0.45 ± 0.08 μg/mL for *Lycoris radiata* agglutinin. Although the exact mechanism of action was not determined, activity at the stage of viral attachment or the end of the infectious viral cycle were deemed to be the most likely targets. In clinical trials, other lectins have demonstrated reasonable to good tolerability ([@bib0380]), hence with further testing, they may prove to be one of the more promising classes of naturally derived compound(s) for the treatment of SARS-CoV-2 and other coronavirus infections.

### 3.2.5. Increasing potency via chemical modification {#sec0050}

Whilst many natural derived compounds show considerable promise for the inhibition of SARS-CoV and other human coronaviruses, few approach the level of efficacy and/or selectivity required for commercial drugs. For example, the calpain inhibitor MDL28170 has been shown to have an IC~50~ value of just 2.5 nM (∼1 ng/mL) in its activity against the SARS-CoV enzyme cathepsin-L ([@bib0410]). Cathepsin-L is a cysteine protease which is an important lysosomal endopeptidase enzyme involved in the initiation of protein degradation ([@bib0425]) and mediates entry and infection of SARS-CoV in its host cells ([@bib0120]). Chemical modification of naturally-derived compounds may be required to increase the potency of their antiviral activity to levels suitable for therapeutic application. For the drug discovery process, beginning with the understanding of the structural conformity (i.e. structure including potential isomers) of the naturally derived compound(s) can reduce timelines and greatly increase the chance of finding effective viral inhibitors.

Working on this principle, [@bib0105] found that modification of glycyrrhizin, naturally found in liquorice and previously used for the treatment of SARS-CoV ([@bib0085]), could increase its viral inhibition activity. For example, adding 2-acetamido-β-*D*-glucopyranosylamine to the glycoside chain of glycyrrhizin increased its antiviral activity in a CPE assay by 10-fold (decrease in EC~50~ from 365 ± 12 μM to 40 ± 13 μM), through increased attraction to the S proteins. Amides and conjugates with amino acid residues and free COOH increased activity of glycyrrhizin by up to 70-fold (EC~50~ for CPE assay ranging from 5 ± 3 μM to 139 ± 20 μM), albeit with significantly reduced selectivity. [@bib0040] demonstrated that tomentins A--E (all naturally occurring compounds) showed viral inhibition activity against SARS-CoV greater as compared to their non-geranylated precursor compounds. Similarly, quercetin-7-rhamnoside ([Fig. 2](#fig0010){ref-type="fig"}) demonstrates over 100 times higher antiviral activity against an animal coronavirus strain compared to its parent compound, quercetin ([@bib0045]).

While the examples of modifications presented here vary, it should not be considered that substitutions are added in a random fashion, but rather performed in the context of targeting a specific receptor or biochemical pathway. For example, the addition of glycosides and specific amino acid residues to glycyrrhizin was performed with the intent of increasing its affinity for the highly glycosylated spike proteins of SARS-CoV. With this in mind, future studies that identify an effective natural inhibitor of coronavirus should also consider the design and testing of potential modifications or synthetic derivatives that could increase its desired activity.

### 3.2.6. The significance of viral strains {#sec0055}

A difference in the efficacy of natural therapeutics, mirroring that observed for commercially/synthetically available drugs, has been observed between coronavirus species/strains. For example, [@bib0370] found that the compound 3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavane, isolated from *Broussonetia papyrifera*, showed good inhibition of PLpro from SARS-CoV (IC~50~ of 3.7 ± 1.6 μM), but not against PLpro from MERS-CoV (IC~50~ of 112.5 ± 7.3 μM). In contrast, the polyphenolics kazinol F and broussochalcone A isolated from the same species showed better efficacy against MERS-CoV PLpro. Similarly, O\'Keefe et al. (2010) found that the efficacy of the compound griffithsin against SARS-CoV was highest for the Urbani and Tor-II strains (EC~50~ of 0.61 μg/mL using a CPE inhibition assay) and lowest for the Frank strain (EC~50~ of 1.19 μg/mL). Griffithsin, isolated from the red alga *Griffithsia* sp., is a lectin possessing three large identical carbohydrate-binding domains orientated as an equatorial triangle, which enable multivalent binding ([@bib0350]). Although the source of these observed differences in the inhibition activity of griffithsin against different SARS-CoV strains was not explored by [@bib0350], it may be attributable to genomic differences in the amino acid sequences of the spike proteins between SARS-CoV strains, leading to varying multivalent interactions with the carbohydrates-binding domains and thus differing affinity for binding to the spike proteins. Nevertheless, these studies highlight the importance of conducting *in vitro* tests of potential naturally-derived therapeutics on SARS-CoV-2 prior to animal or clinical trials.

3.3. Inhibitors of MERS-CoV {#sec0060}
---------------------------

Only a handful of studies have investigated the potential of natural products as therapeutic agents against MERS-CoV. Silvestrol ([Fig. 2](#fig0010){ref-type="fig"}), a phytochemical from *Aglaia* sp., was found to be a more potent inhibitor of MERS-CoV replication (EC~50~ of 1.3 nM) ([@bib0330]). However, no cell-based antiviral assays were performed. Silvestrol is a specific inhibitor of RNA helicase eIF4A, thus inhibiting viral replication and leading to the inhibition of expression of CoV proteins and preventing the formation of replication/transcription complexes ([@bib0330]).

Griffithsin ([Fig. 2](#fig0010){ref-type="fig"}), a 12.7 kDa lectin found in the *Griffithsia* genus (red algae), is one of the most promising inhibitors of MERS-CoV. It comprises three carbohydrate-binding domains which allow it to bind specifically to glycans on CoV protein spikes and inhibit viral attachment to host cells, with high potency found in *in vitro* trials against MERS-CoV (EC~50~ of ∼0.125 μM) (O\'Keefe et al., 2010) and several HCoV strains (EC~50~ of 0.0032−0.33 μM) ([@bib0320]). Griffithsin also appears to have a low systematic toxicity, with its specificity index against HCoV cells (compared to human colorectal adenocarcinoma or fibroblast cell lines) has been estimated at between 30--3100 ([@bib0350]), hence showing the potential to be considered as one of the prime candidates for animal and clinical trials against SARS-CoV-2.

3.4. Inhibitors of other human coronoviruses {#sec0065}
--------------------------------------------

A recent study highlighted the potential anti-HCoV-NL63 activity of the methanolic extract of *Strobilanthes cusia* leaf and its major phytochemicals ([@bib0455]). The *S. cusia* extract effectively reduced virus yield (EC~50~ = 0.64 μg/mL) in cells infected with HCoV-NL63 in a dose-dependent manner. Of the six key compounds isolated, purified and identified via NMR spectroscopy, two exhibited the most potent antiviral activity against HCoV, namely tryptanthrin ([Fig. 2](#fig0010){ref-type="fig"}), a natural alkaloid containing the basic indoloquinazoline moiety, and indigodole B (5aR-ethyltryptanthrin), an indole alkaloid derivative. The EC~50~ values against virus yield from infected cells were 1.52 μM and 2.60 μM for tryptanthrin and indigodole B, respectively. The increased antiviral activity of tryptanthrin in comparison to indigodole B may result from the double bond at C5a in the former, as compared to the additional ethyl moiety in the latter. This highlights that for compounds based on a tryptanthrin structural conformity, addition of a double bond in the quinazoline ring could significantly increase their antiviral activity. Tryptanthrin has previously been found to have a broad spectrum of biological activities including anticancer, anti-inflammatory, antiprotozoal, antiallergic, antioxidant and antimicrobial action ([@bib0155]). Through manipulation of varying modes of time-of-addition/removal assay, it was found that tryptanthrin prevented the early and late stages of HCoV-NL63 replication, particularly by blocking the viral RNA genome synthesis and papain-like protease 2 activity ([Fig. 3](#fig0015){ref-type="fig"}), and inhibiting the post-entry stage of HCoV replication ([@bib0455]). Intriguingly, both tryptanthrin (EC~50~ = 0.06 μM) and indigodole B (EC~50~ = 2.09 μM) exhibited strong viricidal activity directly against HCoV-NL63. As the HCoV-NL63 spike protein (S protein) targets the ACE2 receptor, showing a highly conserved sequence and structural similarity to SARS-CoV and SARS-CoV-2 ([@bib0220]), tryptanthrin has the potential to be explored as a possible bioactive agent against SARS-CoV-2 and other human coronaviruses.

Another recent study on HCoV-OC43 focussed on the antiviral activities of the bis-benzylisoquinoline alkaloids tetrandrine, fangchinoline, and cepharanthine (CPE assay EC~50~ values of 0.33 ± 0.03, 1.01 ± 0.07 and 0.83 ± 0.07 μM, respectively) ([@bib0190]). These compounds were the primary bioactive phytochemicals identified in *Stephania tetrandra* and related species. All compounds were found to inhibit virus-induced cell death, through suppressing viral replication, expression of viral S and N proteins (nucleocapsid protein), and the virus-induced host response. However, the effective inhibitory concentrations were not reported for the inhibition of viral protein expression or host response. In addition, tetrandrine activated the p38MAPK pathway in MRC-5 cells, improving the aforementioned host response.

[@bib0500] tested the ethanolic extracts of *Sambucus formosana* (elderberry) stems against the human coronavirus strain HCoV-NL63, finding quite high efficacy (EC~50~ of 1.17 ± 0.75 μg/mL) for viral yield reduction. With further investigation of the phenolic composition of the extracts and antiviral assays performed on the main individual phenolic acids present, caffeic acid ([Fig. 2](#fig0010){ref-type="fig"}) was identified as the most potent compound present (EC~50~ of 3.54 ± 0.77 μM; or ∼0.64 ± 0.14 μg/mL). Although no specific binding sites were identified, caffeic acid was found to inhibit the attachment of HCoV to host cells, indicating potential binding to S proteins. Caffeic acid has also been found to inhibit other viruses such as hepatitis B ([@bib0485]). Notably, extracts of *Sambucus nigra* (black elderberry), another species in the same genus as *S. formosana*, have been commercialised for the treatment of cold and flu symptoms. Therefore, it is likely that extracts from *S. formosana* would prove similarly nontoxic and suitable for human use, although clinical trials would be required to confirm this. Nevertheless, the bioavailability/delivery mechanism of such extracts would need to be considered in order to reach therapeutic plasma concentrations for viral inhibition ([@bib0510]).

[@bib0030] examined the anticoronaviral activity of saikosaponins (A, B~2~, C and D) and their mode of action against HCoV-229E *in vitro*. Saikosaponins represent a group of pentacyclic triterpenoid derivatives, usually present as glycosides, that have been isolated from medicinal plants such as *Bupleurum* spp., *Heteromorpha* spp. and *Scrophularia scorodonia*, previously found to possess efficacy against several viruses, including human immunodeficiency virus (HIV) ([@bib0035]; [@bib0465]). All saikosaponins tested showed good to moderate anti-coronavirus activity, with saikosaponin B~2~([Fig. 2](#fig0010){ref-type="fig"}) showing the greatest potency (EC~50~ of 1.7 ± 0.1 μM). Subsequent time-of-addition studies indicated that saikosaponin B~2~ inhibited viral attachment and penetration. Interestingly, the same compound has been found to inhibit hepatitis C entry ([@bib0250]) as well as multidrug resistance-associated drug transporters present on the cell surface ([@bib0590]), indicating that it has potential to display a broad spectrum of bioactivity. This may be advantageous in developing nations where hepatitis C prevalence is high ([@bib0375]).

Finally, two compounds that have shown efficacy against MERS-CoV (section [3.3](#sec0060){ref-type="sec"}) also show promise against HCoV. [@bib0330] found that silvestrol ([Fig. 2](#fig0010){ref-type="fig"}) inhibited the translation of HCoV-229E proteins, with an EC~50~ of 3 nM. A follow-up study confirmed that silvestrol can inhibit HCoV-229E in an *ex vivo* bronchial epithelial cell system, with its mechanism of action being the specific inhibition of RNA helicase eIF4A ([@bib0335]). Another compound active against MERS-CoV, griffithsin, also has shown great efficacy against several HCoV strains (EC~50~ of 0.0032−0.33 μM) ([@bib0320]). This again underscores the prospect of exploring griffithsin for antiviral activity against SAR-CoV-2.

4. Animal coronaviruses {#sec0070}
=======================

Animal coronavirus strains are responsible for severe morbidity events across a wide range of domestic animals and livestock, incurring major economic demise worldwide ([@bib0135]; [@bib0215]; [@bib0295]). The genomic diversity, coupled with the ability of coronaviruses to rapidly adapt and mutate, presents unique challenges in the development of novel antiviral agents, hence exploring alternative methods of controlling these viruses could potentially be effective across many or all serotypes. As natural phytochemicals have been shown to have activity across a wide range of viral pathogens ([@bib0020]), they form the basis of the studies reviewed here. The majority of plant-derived compounds considered in this review are direct-targeting antivirals, acting through direct inhibition of some part of the virus, such as proteases or spike proteins. For example, silvestrol prevents viral replication occurring through the specific inhibition of RNA helicase eIF4A ([@bib0330]), while griffithsin binds directly to the S protein, preventing viral entry to the host cell ([@bib0350]). However, host-targeting antivirals form another important group of antiviral compounds. For example, extracts of *Cinnamomi* sp. Inhibit the clathrin-dependent endocytosis pathway, thus preventing viral entry to the host cells ([@bib0595]). Other host-targeting antiviral compounds may stimulate the immune response ([@bib0205]).

[Table 2](#tbl0010){ref-type="table"} presents a summary of studies reporting anti-viral activity of plant-derived isolates against a range of animal coronavirus strains. Where available, the key compounds responsible for the antiviral activity and their mechanism of action are provided.Table 2Studies reporting antiviral activity of natural products or isolates against non-human coronavirus strains.Table 2Viral strainAssay methodPlant speciesPlant part/ isolateEC~50~ or IC~50~ (μM unless otherwise stated)SIKey compounds present (if identified)Biological actionReferenceAvian IBVPlaque assay*Alstonia scholaris*Isolated from 50 % ethanol extract35\>2.8Alstotide 1As1: interferes with membrane and spike proteins but not nucleocapsid proteins([@bib0345])55\>1.8Alstotide 3Avian IBV *Beaudette* strainCPE and plaque assays*Sambucus nigra*70 % ethanol extractNDNDPossibly flavonols or lectinsDisrupts virion structure and compromises membrane integrity([@bib0020])Avian IBV *Beaudette* strainCPE assayn/aQR448(a) (emulsion of oleoresins and essential oils∼1 × 10^−4^ dilution of extractNDNot determinedPossibly disrupt viral membrane or interfere with viral envelope proteins involved in host cell attachment([@bib0135])*In vivo* study in chickensAvian IBV *Beaudette* strainCPE (MTT) assay*Mentha piperita*40 % ethanol0.004 μg/mL67.5Not determinedPossibly direct inactivation of virus envelope structures([@bib0215])*Thymus vulgaris*extract0.010 μg/mL63.1*Desmodium canadense*0.017 μg/mL17.1Avian IBV *Beaudette* strainPlaque assay*Houttuynia cordataH. cordata* solution (essential oils and sodium chloride solution)0.97 mg/mL\>257Main component: methyl-nonyl-ketoneNot determined([@bib0565])*In ovo* and *in vivo* trialsAvian IBV *Gray* strainMTT assayFound in numerous plants, e.g eucalyptsChemical standard used0.61 ± 0.07 mM\>16.39Eucalyptol (1,8-cineole)Interferes with binding between RNA and IBV nucleocapsid protein([@bib0535])Avian IBV *Gray* strainMTT assayFound in coniferous trees. Produced as by-products of the pulp industryChemical standards used0.98 ± 0.25 mM\>10.20(-)-α-pineneMay suppress N-protein, hindering binding process between RNA and IBV N-protein([@bib0540])1.32 ± 0.11 mM\>7.58(-)-β-pineneAvian IBV M41CPE assay and RT-*q*PCRFound in: *Forsythia suspensa*Chemical standard used0.64 mM (complete inhibition)NDForsythoside ANot clear. Appears to affect cell signalling([@bib0230])Bovine coronavirus (BCV)CPE assay*Rosa nutkana*Methanol extract (branches)\<200 μg/mL for bothND*R. nutkana*: NDNot determined([@bib0295])*Amelanchier alnifoliaA. alnifolia*: possibly prunasinFCoV NTU156CPE assay*Galanthus nivalis*Commercial standard0.0088 nM\>218Galanthus nivalis agglutininBinds to spike and membrane proteins([@bib0115])FIPV1146 and FECV1683 (FCoVs)CPE assayn/aCommercial standards\>\>10NDQuercetinNot determined([@bib0300])\>\>10Curcumin\>\>25Rutin\>\>25Glycyrrhizic acid\>\>50Hesperidin\>\>50Hesperitin\>\>10Baicalin\>\>25ArtemisininFIPV1146 (FCoV)Virtual screening followed by 3CLpro inhibition assayFound in: several lichen and plant speciesCommercial standards29.4 ± 4.6n/aStictic acidInhibition of 3CLpro([@bib0435])28.5 ± 4.27-Methylluteolin77.2 ± 13.8Quercetin 7-rhamnoside\>5007-benzyl luteolin\>500SteviolMHV-A59Plaque assay*Cimicifuga racemosa*Methanol extracts19.4 ± 7.012.3Ferulic & isoferulic acid?Inhibit replication of MHV([@bib0175])*Melia* sp.13.0 ± 1.425.6Toosendanin?*Coptidis* sp.2.0 ± 0.534.9Berberine?*Phellodendron* sp.10.4 ± 2.213.4Protoberberine alkaloids?*Sophora subprostrata*27.5 ± 1.1(μg/mL)11.1Matrine, oxymatrine, sophoranone & sophocarpine?MHV-A59Plaque assay*Sophorae* sp.Methanol0.8 ± 0.2696.0Not determinedPossibly inhibitors of RNA-dependent RNA polymerase or other protease activity([@bib0180])Also inhibited MHV-JHM*Acanthopanacis* sp.extracts0.9 ± 0.1188.9*Sanguisorbae* sp.3.7 ± 1.4105.0*Torilis* sp.0.8 ± 0.0(μg/mL)195.6MHV-A59Plaque assay*Punica granatum*Pomegranate juice and ethanol/water extract of powder≥ 200 μg/mLNDPossibly polyphenolsMay interact with surface glycoproteins spikes([@bib0430])MHV-A59RT-*q*PCR*Nigella sativa*Ethanol extractNDNDNot determinedInhibits viral replication via undetermined mechanism([@bib0460])*Anthemis hyalineCitrus sinensis*PEDVCPE assay*Ziziphus jujuba*Compounds isolated from methanol extract13.41 ± 1.13\>30.0Jubanine GNot determined([@bib0150])4.49 ± 0.6747.11Jubanine H6.17 ± 0.5026.75Nummularine BPEDV CV 777CPE assay*Ginkgo biloba*Polysaccharides purified from 98 % ethanol extract1.7 ± 1.3 μg/mL\>58.8Mixture of polysaccharidesDose-dependent inhibition, apparently at viral attachment and entry steps([@bib0210])PEDV CV 777CPE assay*Houttuynia cordata*Compound isolated from methanol extractNDNDQuercetin 7-rhamnosideUncertain. Doesn't obstruct viral mRNA production or interact directly with PEDV([@bib0420])PEDV CV 777CPE assay*Houttuynia cordata*Compounds isolated from methanol extract∼0.03 ± 0.017143Quercetin 7-rhamnosideNot determined([@bib0045])∼5.6 ± 2.6215Quercetin∼0.4 ± 0.4370Apigenin∼0.7 ± 0.732.7LuteolinPEDV (KPEDV-9)CPE assay*Prunus serrulata* var. *spontanea*80 % methanol extract1.95 μg/mLNDPossibly polyphenolsNot determined([@bib0570])PEDV (NJ-PEDV)Immunofluorescence assay and RT-*q*PCRFound in: *Griffithsia* sp.Purified compound used∼0.08NDGriffithsinPrevents viral attachment to host cells([@bib0235])[^3]

4.1. Avian infectious bronchitis virus (IBV) {#sec0075}
--------------------------------------------

The antiviral activity of extracts from plant species against the avian IBV viral strains have been extensively studied ([@bib0020]; [@bib0135]; [@bib0215]; [@bib0230]; [@bib0345]; [@bib0535], [@bib0540]; [@bib0565]). Considering all studies on avian IBV that have established the mechanism of viral inhibition, the main mechanisms of action appear to be through viral envelope disruption or interference with the spike protein ([Table 2](#tbl0010){ref-type="table"}). A notable exception are the terpenoid compounds 1,8-cineole, (-)-α-pinene and (-)-β-pinene, which bind to the IBV nucleocapsid protein (N-protein) ([@bib0535], [@bib0540]), inhibiting its interaction with the viral genomic RNA and breaking the IBV replication cycle. These observations were reinforced by conformational models of the terpenoids binding to the active site at the N terminus of the N protein, which indicated that these compounds have the potential to bind strongly to five amino acid residues at this location (TyrA92, ProA134, PheA137, AspA138 and TyrA140) ([@bib0535], [@bib0540]). As these residues are highly conserved between IBV strains ([@bib0535]), these terpenoids would be expected to show high efficacy against most or all IBV strains, making them a sensible target for further research.

Nevertheless, the envelope protein (E protein) of avian IBV remains the key target for most researchers. The coronavirus E protein is integral to many stages of the viral life cycle, including assembly, budding, envelope formation, and pathogenesis ([@bib0400]). Interestingly, [@bib0020] reported the inactivation of two distinct enveloped viruses (avian IBV and influenza) following treatment with *Sambucus nigra* extract, suggesting that *S. nigra* extract may have the potential to display a broad spectrum of antiviral effects against many other enveloped viruses. Although the authors raised the possibility of synergistic action of inhibitory compounds within the extract, no fractionation, identification or characterisation of the components was performed. However, flavonoids or lectins were suggested as the likely aetiological agents of the antiviral activity.

4.2. Feline coronavirus {#sec0080}
-----------------------

Feline coronavirus is another coronavirus in the Alphacoronavirus group, causing a fatal disease in cats with no effective antiviral treatments available. In one study, *Galanthus nivalis* agglutinin, another lectin, was identified as a potent inhibitor of feline coronavirus (FCoV) ([@bib0115]). With an EC~50~ of just 0.0088 nM and a high selectivity index (\>218), this carbohydrate-binding protein outperformed all synthetic antiviral agents tested for comparison purposes. For example, the protease inhibitor nelfinavir displayed an EC~50~ of 8.19 μM and a selectivity index of just 1.4. As with other agglutinins, *Galanthus nivalis* agglutinin binds to the spike and membrane proteins of FCoV, preventing their attachment to the host cells.

[@bib0300] conducted a screening study against 19 compounds, focusing on those demonstrated to have previous antiviral effects against coronaviruses or other RNA viruses. Several naturally occurring compounds were included in this study, such as quercetin, curcumin, rutin, glycyrrhizic acid, hesperidin, hesperitin, baicalin and artemisinin. However, none of these compounds reached EC~50~ at the concentrations tested. Glycyrrhizic acid was the most promising, causing a 26.7 % reduction in CPE at a concentration of 25 μM. As only a single concentration was tested for each compound (ranging from 10 to 50 μM, depending on the compound), further investigation of these compounds against FCoV is required.

[@bib0435] adopted a computer-aided approach to their screening study against feline infectious peritonitis virus (FIPV), a mutated form of the parental enteric form of FCoV. Firstly, compounds from a chemical library were virtually screened for potential binding to the protease 3CL. The 15 most promising compounds were then evaluated *in vitro* using a protease inhibitor assay against FIPV 3CL^pro^. Of the naturally occurring compounds tested, the lowest IC~50~ values were shown by 7-methylluteolin (28.5 ± 4.2 μM) and stictic acid (29.4 ± 4.6 μM). Quercetin 7-rhamnoside ([Fig. 2](#fig0010){ref-type="fig"}) also showed moderate inhibition (IC~50~ of 77.2 ± 13.8 μM); however 7-benzyl luteolin and steviol showed no inhibition (IC~50~ \> 500 μM). Subsequent testing of the active compounds using a cytopathic effect (CPE) assay indicated that only stictic acid protected cells from viral-induced death (EC~50~ for pre-viral entry treatment of 16.24 ± 1.33 μM; selectivity index of 23).

4.3. Porcine endemic diarrhoea virus (PEDV) {#sec0085}
-------------------------------------------

Porcine endemic diarrhoea virus is another serious coronavirus from the Alphacoronavirus group. Several studies have investigated the activity of phytochemicals against murine coronaviruses (strain MHV-A59), the most extensive of which were performed by [@bib0175] and [@bib0180]. Nevertheless, none of the studies of this viral strain have conclusively managed to determine the specific compounds responsible for viral inhibition, but rather suggested possible compounds or classes of compounds based on their abundance in the extracts tested. The low inhibitory concentrations (\<1 μg/mL) of extracts obtained from *Sophorae* sp., *Acanthopanacis* sp. and *Torilis* sp. appear to show significant potential. In particular, the high viral specificity (SI = 696) of *Sophorae* sp. root extracts suggests that it could be considered as a prime candidate for future studies on the screening and isolation of compounds from the aforementioned species. The authors suggested that the antiviral activity of these three species are likely to be occurring through inhibition of RNA-dependent RNA polymerase or other protease activity.

Six studies considered natural agents active against porcine endemic diarrhea virus (PEDV), with the majority of these identifying the compounds with for their antiviral activity. In particular, the anti-PEDV activity of griffithsin and quercetin ([Fig. 2](#fig0010){ref-type="fig"}) and its derivatives deserve particular discussion, given that these compounds have also been found to have antiviral activity against human CoVs ([@bib0320]; O\'Keefe et al., 2010; [@bib0495]). Notably, quercetin was also one of the compounds shortlisted by [@bib0580] in their virtual screening of inhibitors of SARS-CoV-2 proteases. Against PEDV, quercetin-7-rhamnoside, a disaccharide glucoside, provided 50 % inhibition of viral activity at a concentration of just 0.03 μM, approximately 187 times lower than quercetin alone ([@bib0045]). Significantly, the specificity of quercetin-7-rhamnoside was exceptionally high (SI = 7143), indicating its potential for application in future animal or clinical trials. This study again highlights the importance of considering all possible structural conformities of a compound, including glycosides, in order to identify the most bioactive chemical species. Although the mechanism of action was not determined for quercetin or quercetin-7-rhamnoside against PEDV, previous computer modelling work has indicated that quercetin binds to and inhibits the SARS-CoV proteases PLpro and 3CLpro ([@bib0580]). As previously determined, griffithsin binds to the spike protein of CoV, preventing attachment to host cells ([@bib0320]; O\'Keefe et al., 2010).

In general, most authors recommend testing multiple coronavirus strains when searching for antiviral activity in naturally occurring compounds. Similarly important is determining their specific mechanism of action. As highlighted by several studies, a selection of compounds that are active against animal coronaviruses are also active against human coronavirus strains (e.g. griffithsin, quercetin). This underscores the potential of utilising compounds with identified activity against animal coronaviruses to guide the discovery of drugs against human coronaviruses, in addition to identifying drugs for the treatment of economically significant animal coronaviruses such as PEDV and avian IBV.

5. The significance of chemical polarity {#sec0090}
========================================

Across both human and animal CoV strains, a clear trend toward the use of chemically polar compounds is evident ([Fig. 2](#fig0010){ref-type="fig"}). Of the 30 studies that specified the solvent extraction protocols used, ethanol or an ethanol/water combination was the most commonly used (50 % of all studies), followed by methanol or a methanol/water combination (27 %). A further 17 % of relevant literature used a water-based extraction protocol, with only three studies using relatively non-polar solvents (diaminopropane, chloroform and acetone). This is consistent with a wide body of research indicating that relatively polar extracted fractions generally contain a greater level of bioactive and antimicrobial compounds compared to their nonpolar counterparts ([@bib0095]; [@bib0440]; [@bib0505]). This may also be indicative of increased bioactivity of highly polar glycosylated compounds, similar to the vast difference in antiviral activity observed between quercetin and quercetin-7-rhamnoside ([@bib0045]).

In the case of compounds being administered orally, more polar compounds are subject to compartmentalisation within the body, reducing their rate of elimination. However, the potential chemical changes that could occur as a result of highly acidic stomach conditions and the level of absorption in the intestine would need to be considered individually for each compound.

6. Conclusions {#sec0095}
==============

Naturally occurring phytochemicals provide a valuable and powerful resource of chemical compounds displaying antiviral properties. Further chemical modification of these structures, guided by computer-based docking simulations, may also increase their potency and/or selectivity. Some of the key compounds that show promise for the treatment of coronavirus in humans include scutellarein, silvestrol, tryptanthrin, saikosaponin B~2~, lectins such as griffithsin, lycorine and polyphenolics -- including quercetin, myricetin, caffeic acid, psoralidin and isobavachalcone. Needless to mention, these compounds may be toxic at certain levels, and hence *in vitro* and *in vivo* testing is required to determine safe and therapeutic levels for each compound before clinical trials in humans can be performed. Initial studies could focus on compounds which have previously been approved for drug use, or are generally regarded as safe by the FDA or other national organisations, as is the case for some polyphenolic compounds. It is hoped that researchers will be guided by this information presented here in the process of developing safe, effective anti-coronavirus therapeutic agents from naturally derived compounds.

Funding sources {#sec0100}
===============

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest
=================================

The authors declare that no conflict of interest exists.

[^1]: these authors contributed equally to the manuscript.

[^2]: CLpro  = chymotrypsin-like protease; CPE assay = cytopathogenic effect assay; n/a = not applicable to this study; ND = no data; PLpro = papain-like protease.

[^3]: BCV = bovine coronavirus; CPE assay = cytopathogenic effect assay; FCoV = feline coronavirus; IBV = (avian) infectious bronchitis virus; MHV = mouse hepatitis virus; n/a = not applicable to this study; ND = no data; PEDV = porcine epidemic diarrhoea virus.
